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Abstract
Background Monitoring cerebrovascular reactivity in adult traumatic brain injury (TBI) has been linked to global patient
outcome. Three intra-cranial pressure (ICP)-derived indices have been described. It is unknown which index is superior for
outcome association in TBI outside previous single-center evaluations. The goal of this study is to evaluate indices for 6- to 12-
month outcome association using uniform data harvested in multiple centers.
Methods Using the prospectively collected data from the Collaborative European NeuroTrauma Effectiveness Research in TBI
(CENTER-TBI) study, the following indices of cerebrovascular reactivity were derived: PRx (correlation between ICP and mean
arterial pressure (MAP)), PAx (correlation between pulse amplitude of ICP (AMP) and MAP), and RAC (correlation between
AMP and cerebral perfusion pressure (CPP)). Univariate logistic regression models were created to assess the association
between vascular reactivity indices with global dichotomized outcome at 6 to 12 months, as assessed by Glasgow Outcome
Score–Extended (GOSE). Models were compared via area under the receiver operating curve (AUC) and Delong’s test.
Results Two separate patient groups from this cohort were assessed: the total population with available data (n = 204) and only
those without decompressive craniectomy (n = 159), with identical results. PRx, PAx, and RAC perform similar in outcome
association for both dichotomized outcomes, alive/dead and favorable/unfavorable, with RAC trending towards higher AUC
values. There were statistically higher mean values for the index, % time above threshold, and hourly dose above threshold for
each of PRx, PAx, and RAC in those patients with poor outcomes.
Conclusions PRx, PAx, and RAC appear similar in their associations with 6- to 12-month outcome in moderate/severe adult TBI,
with RAC showing tendency to achieve stronger associations. Further work is required to determine the role for each of these
cerebrovascular indices in monitoring of TBI patients.
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Introduction
Various continuous indices for monitoring cerebrovascular reac-
tivity exist[2, 7, 20]. These indices are derived from the different
cranial multi-modal monitoring (MMM) devices employed for
the monitoring of critically ill patients. In the traumatic brain
injury (TBI) literature, the indices derived from invasive intra-
cranial pressure (ICP)monitoring are themost widely described,
with pressure reactivity index (PRx—the correlation between
ICP and mean arterial pressure (MAP)) considered a standard,
and widely applied, index for monitory cerebrovascular reactiv-
ity in adult TBI [1, 3, 6–9, 13, 16, 18, 20, 22].
The literature supports a strong association between PRx and
global patient outcome in adult TBI, [7, 18] with experimental
literature validating it as a measure of cerebral autoregulation [4,
19, 23]. However, two other ICP-derived indices exist: pulse
amplitude index—PAx (correlation between pulse amplitude
of ICP (AMP) andMAP) [2] and RAC (correlation (R) between
AMP (A) and cerebral perfusion pressure (CPP)) [21]. Both of
these newer indices have also been validated as measures of
cerebral autoregulation in experimental animal models [19,
23]. However, it must be noted that all three of these ICP-
derived indices have only been validated against the lower limit
of autoregulation, [4, 19, 23] with literature validating their abil-
ity to detect the upper limit currently unavailable.
Some preliminary literature based on single-center retro-
spective study supports the superiority of RAC in its associa-
tion with 6-month global outcome, over both PRx and PAx, in
adult TBI [22]. The goal of this multi-center study, using the
high-resolution intensive care unit (ICU) cohort from the
Collaborative European Neuro Trauma Effectiveness
Research in TBI (CENTER-TBI) study, [15] was to determine
which ICP index of cerebrovascular reactivity is superior in its
association with 6- to 12-month global outcome in adult TBI,
evaluating raw index values and derived parameters.
Methods
Patient population
All patients from the multi-center CENTER-TBI high-
resolution ICU cohort were included for this study. These
patients were prospectively recruited during the periods of
January 2015 to December 2017. A total of 21 centers in the
European Union (EU) recruited patients for this cohort. All
patients were admitted to ICU for their TBI during the course
of the study, with high-frequency digital signals recorded from
their ICU monitors during the course of their ICU stay. All
patients predominantly suffered from moderate to severe TBI
(moderate = Glasgow Coma Score (GCS) 9 to 12 and severe =
GCS of 8 or less). A minority of patients suffered from non-
severe TBI, with subsequent early deterioration leading to
ICU admission for care and monitoring. All patients in this
cohort had invasive ICP monitoring conducted in accordance
with the BTF guidelines [5].
Ethics Data used in these analyses were collected as part of the
CENTER-TBI study which had individual national or local
regulatory approval; the UK ethics approval is provided as an
exemplar: (IRAS No: 150943; REC 14/SC/1370). The
CENTER-TBI study (EC grant 602150) has been conducted
in accordance with all relevant laws of the EU if directly appli-
cable or if direct effect and all relevant laws of the country
where the recruiting sites were located, including but not limit-
ed to, the relevant privacy and data protection laws and regula-
tions (the “Privacy Law”), the relevant laws and regulations on
the use of humanmaterials, and all relevant guidance relating to
clinical studies from time to time in force including, but not
limited to, the ICH Harmonised Tripartite Guideline for Good
Clinical Practice (CPMP/ICH/135/95) (“ICH GCP”) and the
World Medical Association Declaration of Helsinki entitled
“Ethical Principles for Medical Research Involving Human
Subjects”. Informed consent by the patients and/or the legal
representative/next of kinwas obtained, accordingly to the local
legislations, for all patients recruited in the Core Dataset of
CENTER-TBI and documented in the e-CRF.
Data collection
As part of recruitment to the multi-center high-resolution ICU
cohort of CENTER-TBI, [15] all patients had demographics
prospectively recorded. Similarly, all patients had high-
frequency digital signals from ICU monitoring recorded
throughout their ICU stay, with the goal of initiating recording
within 24 h of injury. All digital ICU signals were further
processed (see “Signal acquisition” and “Signal processing”).
For the purpose of this study, the following admission demo-
graphic variables were collected: age, sex, and admission
Glasgow Coma Scale (GCS—total and motor). Data was
accessed on Sept 16th, 2018 via Opal database software [10].
Signal acquisition
Arterial blood pressure (ABP) was obtained through either
radial or femoral arterial lines connected to pressure transduc-
ers (Baxter Healthcare Corp. CardioVascular Group, Irvine,
CA). ICP was acquired via an intra-parenchymal strain gauge
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probe (Codman ICP MicroSensor; Codman & Shurtleff Inc.,
Raynham, MA), parenchymal fiber optic pressure sensor
(Camino ICP Monitor, Integra Life Sciences, Plainsboro, NJ,
United States; https://www.integralife.com/), or external
ventricular drain. All signals were recorded using digital
data transfer or digitized via an A/D converter (DT9801;
Data Translation, Marlboro, MA), where appropriate,
sampled at frequency of 100 Hz (Hz) or higher, using the
ICM+ software (Cambridge Enterprise Ltd., Cambridge,
UK, http://icmplus.neurosurg.cam.ac.uk) or Moberg CNS
Monitor (Moberg Research Inc., Ambler, PA, USA) or a
combination of both. Signal artifacts were removed using
both manual and automated methods prior to further
processing or analysis.
Physiologic signals were recorded throughout the duration
of ICP monitoring for the patients, with initiation of recording
within 24 h of the injury. For the patients undergoing decom-
pressive craniectomy, there were 45 in this cohort. Seventeen
patients had secondary decompressive craniectomies (i.e., for
refractory ICP), and thus had recordings both pre- and post-
craniectomy. The remaining 28 underwent primary
craniectomies near the time of admission, and thus only had
physiologic signals recorded for the periods after craniectomy.
Signal processing
Post-acquisition processing of the above signals was conduct-
ed using ICM+. CPP was determined as CPP =MAP–ICP.
AMP was determined by calculating the fundamental
Fourier amplitude of the ICP pulse waveforms over a 10 s
window, updated every 10 s. Ten-second moving averages
(updated every 10 s to avoid data overlap) were calculated
for all recorded signals: ICP, ABP (which produced MAP),
AMP, and CPP. This 10-s moving average filter is applied to
the raw signals so as to decimate signal frequency into the
range appropriate for vasogenic slow-wave evaluation (i.e.,
0.05 to 0.005 Hz) [11, 12].
Continuous indices of cerebrovascular reactivity were de-
rived via the moving correlation coefficient between 30 con-
secutive 10 s mean windows (i.e., vasogenic slow-wave fluc-
tuations) of the parent signals, updated every minute. PRx was
derived via the correlation between slow-wave fluctuations
(i.e., 0.05 to 0.005 Hz) in ICP and MAP [7, 11, 12]. PAx
was derived via the correlation between slow-wave fluctua-
tions in AMP and MAP. RAC was derived via the correlation
between slow-wave fluctuations in AMP and CPP. The focus
on slow-wave frequency range (i.e., 0.05 to 0.005 Hz) is con-
ducted to evaluate the vasogenic responses in the cerebrovas-
cular system, with this frequency range validated in the liter-
ature to provide the optimal discriminatory frequency for
phase-shift between signals [11, 12].
PRx has been thoroughly described in the TBI literature,
with numerous publications to date [7, 16, 18, 20, 22]. PAx
has been sparingly described and has displayed potential su-
periority over PRx in patients with persistently low ICP
throughout their ICU stay [2, 22]. RAC is a newly described
index which provides some suggestion of stronger association
with 6-month outcome, compared to PRx and PAx [21, 22]. In
general, these moving correlation coefficients between slow-
wave fluctuations (i.e., frequency range of 0.05 to 0.005 Hz)
[11, 12] in a measure of pulsatile cerebral blood volume, such
as ICP or AMP, and a driving pressure to blood flow, such as
MAP or CPP, provide information regarding cerebrovascular
reactivity, with all three having some validation in experimen-
tal models of arterial hypotension [4, 23] and/or intra-cranial
hypertension [19] as measures of the lower limit of autoregu-
lation. These indices range from + 1.0, which typically de-
notes severely impaired cerebral autoregulation, to − 1.0,
denoting intact autoregulation [20]. Various critical thresholds
associated with 6-month outcome for each index have been
described in the clinical literature [18, 22].
Data was provided in minute-by-minute comma separated
variable sheets for the entire duration of ICP recording for
each patient. The median recording duration for the included
patients was 136.0 h (IQR: 90.2 to 182.3 h).
Data processing
Grand mean values of all physiologic variables were calculat-
ed per patient. In addition, the following post-ICM+ process-
ing of this physiologic data occurred in R (R Core Team
(2016). R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria.
URL https://www.R-project.org/):
Cerebrovascular reactivity indices
a. PRx—For each patient, the % of time spent above the
following clinically defined thresholds was calculated
across the entire recording period: 0, + 0.25, + 0.35. In
addition, mean hourly dose of PRx above each of these
thresholds was calculated.
b. PAx—for each patient, the % of time spent above the
following clinically defined thresholds was calculated
across the entire recording period: 0, + 0.25. In addition,
mean hourly dose of PAx above each of these thresholds
was calculated.
c. RAC—For each patient, the % of time spent above the
following clinically defined thresholds was calculated
across the entire recording period: − 0.10, − 0.05. In
addition, mean hourly dose of RAC above each of
these thresholds was calculated.
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Statistics
All statistical analysis was conducted using R (R Core
Team (2016). R: A language and environment for statisti-
cal computing. R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org/) and
XLSTAT (Addinsoft, New York, NY; https://www.xlstat.
com/en/) add-on package to Microsoft Excel (Microsoft
Office 15, Version 16.0.7369.1323). Normality of contin-
uous variables was assessed via Shapiro-Wilks test. For
all testing described within, the alpha was set at 0.05 for
significance.
Despite GOSE being collected at both 6- and 12-month
post-injury in this cohort of patients, there was missing
data present in both categories of outcome. At the time
point of data access for this study (Sept 2018), imputed
global outcomes were not available for this cohort and are
currently still to focus of a separate ongoing larger project
on data imputation in CENTER-TBI, including the small
number of high-resolution patients and the larger non-
high-resolution ICU cohorts. Thus, we combined GOSE
scores from both 6 and 12 months in order to provide a “6
to 12 Month” GOSE. For patients where GOSE was re-
ported for both 6 and 12 months, the later GOSE score
was selected for analysis. GOSE was then dichotomized
into the following categories: (a) alive (GOSE 2 to 8) vs.
dead (GOSE 1) and (b) favorable (GOSE 5 to 8) vs. un-
favorable (GOSE 4 or less). Demographics and physio-
logic variables were compared between each dichoto-
mized group, via t test, Mann-U, and Chi-square testing
where appropriate.
Univariate logistic regression (ULR) was conducted,
comparing each ICP cerebrovascular reactivity index vari-
able (i.e., mean index value, % time above threshold, and
mean hourly dose above threshold) to both dichotomized
outcomes, assessing superiority via AUC and Delong’s test.
Multi-variable models were not created in this study, as the
focus was on univariate association with global outcome, in
order to provide some validation for previous retrospective
single-center work on ICP-derived indices of cerebrovascu-
lar reactivity [18, 22] and inform future planned multi-
variable analysis.
Results
Patient population
At the time of this analysis, a total of 204 patients from the
CENTER-TBI high-resolution ICU cohort had complete data
sets, including: 6- to 12-month GOSE and high-frequency
physiologic signals containing at least ICP and ABP for ICP
cerebrovascular index derivation. A total of 159 patients did
not undergo decompressive craniectomy (DC). The analysis
was conducted in both the total population (n = 204) and the
non-DC cohort (n = 159), yielding similar results. The patient
demographics for the entire cohort can be found summarized
in Table 1. Mann-U and Chi-square testing comparing various
variables between the dichotomized outcome groups can be
seen in Tables 2 and 3. Furthermore, the non-DC patient co-
hort demographic and comparison between groups can be
found in Appendix A of the supplementary materials.
Comparison between dichotomized outcome groups
Identical statistically significant differences between dichoto-
mized outcome groups were noted in both the total population
and the non-DC cohort (see Tables 3, 4 and Appendix A). In
general, for the alive/dead outcome groups, the following
were statistically higher for the death group: age, mean ICP,
% time with ICP > 20 mmHg, % time with ICP > 22 mmHg,
mean PRx, mean PAx, mean RAC, mean % time above all
index thresholds, and mean hourly dose above all index
thresholds.
Comparing favorable/unfavorable outcome groups, the sta-
tistically significant differences in variables were the same,
with the exception for ICP-based variables (mean ICP, % time
with ICP > 20 mmHg and > 22 mmHg), where these were not
significantly different between groups.
Univariate logistic regression analysis
Exploring just the ICP-based cerebrovascular reactivity index
variables (i.e., mean index value, % time above threshold, and
mean hourly dose above threshold) and their associations with
dichotomize outcomes, identical results were seen for both the
total population and the non-DC cohort. Overall, the AUCs
for RAC-based variables were higher in association with both
alive/dead and favorable/unfavorable outcomes, as displayed
in Table 4 (total population) and Appendix B of the supple-
mentary materials (non-DC cohort). However, comparing
AUCs, there was no statistically significant difference be-
tween PRx, PAx, or RAC, when comparing similar variables
(i.e., mean value, % time above thresholds, hourly dose above
threshold). Thus, when assessing the core indices for outcome
association, all three perform similarly, with RAC trending
towards higher AUCs.
Discussion
Using the high-resolution ICU cohort from the multi-center
CENTER-TBI study, we have performed a basic analysis of
the outcome association of the three ICP-derived cerebrovas-
cular reactivity indices (PRx, PAx, and RAC) in adult
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moderate/severe TBI. Some interesting results deserve
highlighting.
Using both the total patient population and those without
DC, all ICP-derived indices performed similarly in their out-
come association capacity for both 6- to 12-month dichoto-
mized outcomes. The variables derived from the indices and
their known critical thresholds were all statistically signifi-
cantly associated with both outcomes of interest. RAC vari-
ables (i.e., mean RAC, % time above threshold, and mean
hourly dose of RAC above threshold) overall displayed the
highest AUCs compared to those similar variables derived
from PRx and PAx. This, however, was not statically different
when comparing the AUC’s via Delong’s test. Thus, all core
index variables performed similarly in outcome association,
with a trend to higher AUCs for RAC. These results are in
keeping with a previous large retrospective cohort analysis
conducted to evaluate these three indices [22]. This lack of
statistical significance between AUCs may be a function of
the relatively lower patient numbers, 204 for total population
and 159 for non-DC cohort. Previous retrospective single-
center comparisons were based on much larger cohorts (n =
358) [7, 18, 22]. Further, larger studies in patients with this
type of high-resolution data is required to confirm credibility
of our results. Such larger multi-center studies are in the
Table 1 Patient demographics–
total population Median (IQR)
Number of patients 204
Age (years) 47.5 (29 to 62.3))
Sex Male 163
Female 41
Admission GCS (total) 7 (4 to 13)
Admission GCS motor 4 (2 to 6)
Duration of high-frequency cranial physiologic recording (hours) 136.0 (90.2 to 182.3)
ICP (mmHg) 12.2 (9.3 to 15.4)
CPP (mmHg) 70.9 (64.4 to 76.8)
% Time with ICP > 20 mmHg 4.7 (0.9 to 15.7)
% Time with ICP > 22 mmHg 2.8 (0.5 to 9.7)
Mean PRx 0.038 (− 0.071 to 0.164)
Mean PAx − 0.030 (− 0.169 to 0.093)
Mean RAC − 0.296 (− 0.484 to − 0.129)
% Time with PRx > 0 52.5 (40.2 to 67.8)
% Time with PRx > + 0.25 28.1 (19.1 to 41.4)
% Time with PRx > + 0.35 21.1 (14.0 to 31.2)
% Time with PAx > 0 45.8 (30.8 to 62.0)
% Time with PAx > + 0.25 21.0 (12.4 to 35.4)
% Time with RAC> − 0.10 27.0 (14.0 to 44.9)
% Time with RAC> − 0.05 22.5 (11.8 to 39.9)
Mean hourly dose of PRx > 0 8.9 (6.3 tot 13.0)
Mean hourly dose of PRx > + 0.25 3.7 (2.5 to 5.8)
Mean hourly dose of PRx > + 0.35 2.5 (1.5 to 3.9)
Mean hourly dose of PAx > 0 6.4 (4.0 to 10.2)
Mean hourly dose of PAx > + 0.25 2.3 (1.2 to 3.9)
Mean hourly dose of RAC> − 0.10 3.6 (1.9 to 7.1)
Mean hourly dose of RAC> − 0.05 3.0 (1.5 to 6.0)
6- to 12-month GOSE 4 (2 to 6)
Number alive—6 to 12 months 155
Number dead—6 to 12 months 49
Number favorable outcome—6 to 12 months (GOSE 5 to 8) 109
Number unfavorable outcome—6 to 12 months (GOSE 1 to 4) 96
AMP pulse amplitude of ICP, CPP cerebral perfusion pressure, GCS Glasgow Coma Score, GOSE Glasgow
Outcome Score, ICP intra-cranial pressure, IQR inter-quartile range, MAP mean arterial pressure, mmHg milli-
meters of mercury, PAx pulse amplitude index (correlation between AMP and MAP), PRx pressure reactivity
index (correlation between ICP and MAP), RAC correlation between AMP and CPP
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planning phase and not currently underway. However, when
such studies are running, it will be imperative to ensure that
such complex high-frequency physiologic data is curated in
such a way that allows for sharing between centers globally. It
is only through such global initiatives, with standards in com-
plex data collection/curation, that we will be able to produce
large enough data sets to begin to definitively answer our
questions related to metrics derived for high-frequency digital
physiologic information.
Comparing all three ICP-derived indices of cerebrovascu-
lar reactivity, they all performed similarly in their association
with both dichotomized outcomes. This is in keeping with the
only other study published evaluating all three indices in a
single population [22]. As such, these findings were not a
surprise, but confirmatory. There was a trend, as mentioned,
for AUCs related to RAC to be higher. This was also seen in
the previous retrospective work [22]. Thus, the next question
may be why? All three indices have been validated as mea-
sures of the LLA in experimental models of arterial hypoten-
sion and/or intra-cranial hypertension [4, 19, 23]. Therefore, it
is not surprising that they carry similar information regarding
vascular reactivity, and thus perform similarly in clinical stud-
ies when assessing outcome prediction. It is currently un-
known if one index is superior to another in adult TBI. This
would require much larger high-resolution patient popula-
tions, allowing various sub-population analyses to be per-
formed, including but not limiting such sub-population anal-
yses to those with persistently low ICP, persistently high ICP,
Table 2 Alive/dead
dichotomized groups—Mann-U
and Chi-square comparison
between groups
Mean/Median (± sd or IQR) p value
Alive Dead
Number of patients 155 49
Age (years) 43.5 (18.4) 56.6 (18.7) < 0.0001
Sex Male 128 35 0.089
Female 27 13
Admission GCS (total) 7 (5 to 13) 8 (3 to 13) 0.707
Admission GCS motor 4 (2 to 5) 4 (1 to 6) 0.863
Duration of high-frequency physiologic recording (hours) 164.1 (118.5) 145.1 (96.6) 0.472
ICP (mmHg) 12.2 (5.9) 19.9 (15.6) 0.028
CPP (mmHg) 71.1 (8.8) 66.6 (17.5) 0.583
% Time with ICP > 20 mmHg 10.7 (18.5) 32.4 (35.5) 0.025
% Time with ICP > 22 mmHg 7.1 (15.2) 27.6 (34.0) 0.012
Mean PRx 0.017 (0.150) 0.226 (0.269) < 0.0001
Mean PAx − 0.064 (0.175) 0.126 (0.223) < 0.0001
Mean RAC − 0.347 (0.241) − 0.114 (0.276) < 0.0001
% Time with PRx > 0 50.2 (16.7) 66.6 (20.5) < 0.0001
% Time with PRx > + 0.25 28.5 (14.1) 48.0 (25.0) < 0.0001
% Time with PRx > + 0.35 21.4 (12.2) 41.0 (25.7) < 0.0001
% Time with PAx > 0 42.7 (18.7) 59.8 (20.9) < 0.0001
% Time with PAx > + 0.25 21.6 (14.6) 39.6 (22.9) < 0.0001
% Time with RAC> − 0.10 27.7 (20.1) 46.8 (23.7) < 0.0001
% Time with RAC> − 0.05 24.6 (18.8) 43.3 (23.5) < 0.0001
Mean hourly dose of PRx > 0 9.1 (4.6) 15.7 (11.9) 0.001
Mean hourly dose of PRx > + 0.25 3.9 (2.6) 8.7 (8.8) 0.001
Mean hourly dose of PRx > + 0.35 2.6 (1.9) 6.6 (7.5) 0.001
Mean hourly dose of PAx > 0 6.7 (4.3) 12.1 (8.9) 0.001
Mean hourly dose of PAx > + 0.25 2.5 (2.2) 6.0 (5.9) < 0.0001
Mean hourly dose of RAC> − 0.10 4.4 (4.2) 9.6 (8.3) < 0.0001
Mean hourly dose of RAC> − 0.05 3.8 (3.7) 8.5 (7.7) < 0.0001
AMP pulse amplitude of ICP, CPP cerebral perfusion pressure, GCS Glasgow coma score, GOSE Glasgow
outcome score, ICP intra-cranial pressure, IQR inter-quartile range,MAPmean arterial pressure, mmHgmillime-
ters of mercury, PAx pulse amplitude index (correlation between AMP and MAP), PRx pressure reactivity index
(correlation between ICP and MAP), RAC correlation between AMP and CPP, sd standard deviation
Italicized p values are those reaching statistical significance (i.e., p < 0.05)
1222 Acta Neurochir (2019) 161:1217–1227
those with craniectomy (both primary and secondary), those
with various types of intra-cranial pathology (i.e., for example
patients with contusions versus diffuse axonal injury, etc),
variation in systemic fluid volume, and those with various
types of ICU therapies on board (i.e., sedatives, barbiturates,
vasopressors, CSF drainage, and hypothermia). As such, at
this time, it remains uncertain which index is superior in adult
TBI.
Finally, strictly evaluating the difference in mean values for
variables between both dichotomized groups, it is clear that
the cerebrovascular reactivity indices are far worse in those
with poorer outcomes. The mean values, % time above thresh-
old, and hourly dose above threshold were statistically higher
for both those patients who died and had unfavorable out-
comes. This is in contrast to the ICP variables (i.e., % time
with ICP > 20 mmHg and % time with ICP > 22 mmHg),
where the percentage of time above ICP threshold appears to
only be significantly different (i.e., higher) in those patients
whom died, without any statistically significant differences for
these ICP variables noted between favorable and unfavorable
dichotomized outcome groups. This highlights the known
strong relationship between elevated ICP and death in TBI,
with a weaker relation between ICP and long-term functional
outcome [5, 17, 18]. The results from this study suggest that
ICP-derived indices of cerebrovascular reactivity may be bet-
ter predictors of functional outcome in adult TBI, compared to
ICP values alone, emphasizing the potential importance of
cerebrovascular reactivity monitoring in prognostication.
However, the results of this study are preliminary, with these
relationships requiring much further investigation.
Table 3 Favorable/unfavorable
dichotomized groups—Mann-U
and Chi-square comparison
between groups
Mean/median (± sd or IQR) p value
Favorable Unfavorable
Number of patients 95 109
Age (years) 40.9 (17.3) 51.6 (19.6) < 0.0001
Sex Male 85 78 0.463
Female 10 31
Admission GCS (total) 8 (6 to 13) 7 (4 to 11) 0.136
Admission GCS motor 5 (3 to 6) 4 (1 to 6) 0.110
Duration of high-frequency physiologic recording (hours) 151.6 (119.1) 166.5 (108.8) 0.125
ICP (mmHg) 12.7 (6.6) 15.3 (11.7) 0.876
CPP (mmHg) 71.0 (8.9) 68.8 (13.6) 1.000
% Time with ICP > 20 mmHg 11.0 (19.1) 20.3 (29.2) 0.482
% Time with ICP > 22 mmHg 7.4 (16.3) 16.0 (26.7) 0.310
Mean PRx 0.006 (0.153) 0.121 (0.230) 0.001
Mean PAx − 0.082 (0.173) 0.036 (0.219) 0.001
Mean RAC − 0.387 (0.233) − 0.207 (0.269) < 0.0001
% Time with PRx > 0 49.1 (16.9) 58.6 (19.7) 0.002
% Time with PRx > + 0.25 27.5 (14.4) 38.1 (21.4) 0.001
% Time with PRx > + 0.35 20.6 (12.5) 30.9 (21.2) 0.001
% Time with PAx > 0 40.8 (18.4) 52.1 (21.0) 0.001
% Time with PAx >+ 0.25 20.1 (14.2) 31.0 (20.3) < 0.0001
% Time with RAC> − 0.10 24.4 (18.6) 39.1 (23.4) < 0.0001
% Time with RAC> − 0.05 21.7 (17.4) 35.6 (22.8) < 0.0001
Mean hourly dose of PRx > 0 8.7 (4.6) 12.5 (9.1) 0.003
Mean hourly dose of PRx >+ 0.25 3.7 (2.6) 6.3 (6.6) 0.001
Mean hourly dose of PRx >+ 0.35 2.4 (1.9) 4.6 (5.5) 0.001
Mean hourly dose of PAx > 0 6.1 (4.1) 9.6 (7.2) 0.001
Mean hourly dose of PAx > + 0.25 2.3 (2.1) 4.3 (4.5) < 0.0001
Mean hourly dose of RAC> − 0.10 3.7 (3.4) 7.4 (7.0) < 0.0001
Mean hourly dose of RAC> − 0.05 3.1 (2.9) 6.4 (6.4) < 0.0001
AMP pulse amplitude of ICP, CPP cerebral perfusion pressure, GCS Glasgow coma score, GOSE Glasgow
outcome score, ICP intra-cranial pressure, IQR inter-quartile range,MAPmean arterial pressure, mmHgmillime-
ters of mercury, PAx pulse amplitude index (correlation between AMP and MAP), PRx pressure reactivity index
(correlation between ICP and MAP), RAC correlation between AMP and CPP, sd standard deviation
Italicized p values are those reaching statistical significance (i.e., p < 0.05)
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Limitations
Despite the interesting and significant results, there are limi-
tations which require addressing.
First, despite having prospective multi-center data, the
overall patient numbers for the total and non-DC cohorts are
quite low. This may impact the lack of statistical significance
between AUCs found when comparing PRx, PAx, and RAC.
Thus, the results here are only preliminary and require further
validation with larger high-resolution data sets gathered in a
multi-center fashion. This power issue may be further
reflected in the inability to display any statistically significant
differences between admission GCS and the dichotomized
outcome groups. This particular finding was slightly surpris-
ing, given that many other studies have documented worse
admission GCS is associated with worse outcomes at 6 to
12 months post-TBI [7, 14]. This lack of difference is likely
secondary to small patient numbers in the high-resolution ICU
cohort, given the complexity in data curation for this cohort. It
is likely that when future analysis of the entire CENTER-TBI
ICU cohort occurs, where there is no high-frequency physiol-
ogy recorded, that GCS will display significant differences
between dichotomized outcome groups.
Second, treatment heterogeneitymay have played a role in the
signal values and associations seen. CENTER TBI was a pro-
spective observational study, as such there exists a potential for
intra-center and inter-center treatment heterogeneity. In particular,
this study was an observational, not interventional, study, with
the individual centers providing care a level consistent with BTF
and local standards. As such, the heterogeneity in the extent and
aggressiveness of care may have varied between centers. The
aggressiveness of care would impact the duration of monitoring
data obtained, with more aggressive longer-term treatments lead-
ing to extended duration recordings. As such, this treatment het-
erogeneitymay not only impact the recorded physiologic signals,
secondary to the therapies applied to ICP elevations, but also the
Table 4 Univariate logistic
regression analysis–total
population–cerebrovascular
reactivity index based measures
Model AUC A/D (95% CI) p value AUC F/U (95% CI) p value
Mean PRx 0.748 (0.662–x`0.834) < 0.0001 0.649 (0.574–0.724) 0.0002
Mean PAx 0.739 (0.654–0.825) < 0.0001 0.658 (0.583–0.732) < 0.0001
Mean RAC 0.742 (0.661–0.823) < 0.0001 0.691 (0.619–0.763) < 0.0001
% Time above PRx thresholds
% Time above 0 0.731 (0.643–0.818) < 0.0001 0.637 (0.561–0.712) 0.0005
% Time above + 0.25 0.736 (0.648–0.824) < 0.0001 0.647 (0.572–0.722) 0.0002
% time above + 0.35 0.737 (0.648–0.825) < 0.0001 0.651 (0.576–0.726) 0.0002
% Time above PAx threshold
% Time above 0 0.729 (0.644–0.813) < 0.0001 0.656 (0.581–0.730) 0.0001
% Time above + 0.25 0.741 (0.657–0.825) < 0.0001 0.670 (0.596–0.743) < 0.0001
% time above RAC thresholds
% Time above − 0.10 0.736 (0.657–0.816) < 0.0001 0.692 (0.620–0.764) < 0.0001
% Time above − 0.05 0.738 (0.659–0.818) < 0.0001 0.691 (0.619–0.763) < 0.0001
Hourly dose above PRx thresholds
Mean dose above 0 0.680 (0.586–0.774) < 0.0001 0.631 (0.555–0.707) 0.0009
Mean dose above + 0.25 0.696 (0.604–0.787) < 0.0001 0.641 (0.565–0.716) 0.0013
mean dose above + 0.35 0.701 (0.610–0.793) < 0.0001 0.647 (0.572–0.722) 0.0017
Hourly dose above PAx thresholds
Mean dose above 0 0.694 (0.602–0.785) < 0.0001 0.659 (0.585–0.733) 0.0002
Mean dose above + 0.25 0.719 (0.631–0.806) < 0.0001 0.675 (0.602–0.748) 0.0004
Hourly dose above RAC thresholds
Mean dose above − 0.10 0.717 (0.635–0.800) < 0.0001 0.690 (0.618–0.762) < 0.0001
Mean dose above − 0.05 0.720 (0.637–0.803) < 0.0001 0.692 (0.620–0.763) < 0.0001
A/D alive/dead, AMP pulse amplitude of ICP, AUC area under the receiver operating curve, CPP cerebral
perfusion pressure, CI confidence interval, F/U favorable/unfavorable outcome (i.e., favorable = Glasgow out-
come scale of 5 to 8; unfavorable = Glasgow outcome scale of 1 to 4), ICP intra-cranial pressure, IMPACT
International Mission for Prognosis and Analysis of Clinical Trials, MAP mean arterial pressure, PAx pulse
amplitude index (correlation between AMP and MAP), PRx pressure reactivity index (correlation between ICP
and MAP), RAC correlation between AMP and CPP
CORE model consisted of age, admission Glasgow coma scale motor score, and pupil response (normal bilater-
ally, unilateral unreactive, or bilaterally unreactive)
Italicized p values are those reaching statistical significance (i.e., p < 0.05)
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duration of the recordings obtained, and thus potentially the as-
sociations with the dichotomized outcomes seen in our study.
With that said, all other large retrospective studies on cerebrovas-
cular reactivity in the past have been subjected to such limitations
of purely observational data, with their results in parallel to those
found in the current study [7, 18, 22].
Third, the evaluation between systemic volume status, such
as measured through central venous pressure or other meth-
odologies, may prove interesting when compared to cerebro-
vascular reactivity monitoring. There is the potential that fluid
volume may correlate with vascular reactivity as measured
through ICP-derived indices and requires investigation in fu-
ture larger studies.
Fourth, the population chosen was that with an outcome
recorded at 6 to 12 months and high-frequency digital signals,
requiring all patients to have these particular set of variables for
the models, hence the low patient numbers overall. As such,
we utilized the available non-imputed data and focused only on
univariate models comparing various variables to dichoto-
mized outcomes. The focus of this manuscript was on univar-
iate associations with global outcome, in order to provide val-
idation for previous retrospective single-center works on the
topic, [22] while providing insight into these measures for
future work on multi-variable prognostication that will be part
of other works from the CENTER-TBI high-resolution sub-
study. The potential exists for these relationships to become
insignificant when large multi-variable models are assessed.
At the time of this manuscript composition, there is currently
a separate larger project underway for imputation of missing
data components across all cohorts in CENTER-TBI (high
resolution and non-high resolution), the results of which are
not currently available and will be published in a separate
piece. Thus, at this time, all we can comment on are the
strength of univariate associations with outcome, though much
further work on the topic is planned as data becomes available.
Finally, it must be re-emphasized that the results here are
preliminary only given the relatively small patient numbers
and limitations outlined. As such, they require much further
investigation and validation.
Conclusion
PRx, PAx, and RAC appear similar in their associations with
6- to 12-month outcome in moderate/severe adult TBI, with
RAC trending towards higher AUC values. Further work is
required to determine the exact role for each of these cerebro-
vascular indices in monitoring TBI patients.
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